<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Frank A Fish, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Angela J Weingarten, MD, MSCI</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Heidi M Connolly, MD, FACC, FASE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John K Triedman, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4133038380"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tetralogy of Fallot (TOF) includes the following major features  (<a class="graphic graphic_figure graphicRef82493" href="/d/graphic/82493.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Right ventricular (RV) outflow tract obstruction</p><p class="bulletIndent1"><span class="glyph">●</span>Ventricular septal defect (VSD)</p><p class="bulletIndent1"><span class="glyph">●</span>Deviation of the origin of the aorta to the right so that it overrides the VSD</p><p class="bulletIndent1"><span class="glyph">●</span>Concentric RV hypertrophy</p><p></p><p>TOF accounts for approximately 7 to 10 percent of all cases of congenital heart disease and is one of the most common cyanotic congenital heart defects. Morbidity and mortality of TOF have declined markedly with comprehensive management of these patients that includes initial medical care, surgical repair, and long-term management of complications.</p><p>The long-term complications and follow-up after TOF repair are discussed here. Other related topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5770.html" rel="external">"Tetralogy of Fallot (TOF): Management and outcome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5769.html" rel="external">"Tetralogy of Fallot (TOF): Pathophysiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/88284.html" rel="external">"Tetralogy of Fallot with pulmonary atresia and major aortopulmonary collateral arteries (TOF/PA/MAPCAs)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/104752.html" rel="external">"Pulmonic regurgitation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/86481.html" rel="external">"Transcatheter pulmonary valve implantation"</a>.)</p><p></p><p class="headingAnchor" id="H96836544"><span class="h1">SURGICAL REPAIR</span></p><p class="headingAnchor" id="H108333237"><span class="h2">Repair in infancy</span><span class="headingEndMark"> — </span>In the modern era, most patients with TOF undergo primary intracardiac repair in infancy  (<a class="graphic graphic_figure graphicRef67062" href="/d/graphic/67062.html" rel="external">figure 2</a>), typically before six months of age. Historically, TOF repair was performed in two staged procedures: a palliative shunt in early infancy followed by intracardiac repair later in childhood. Primary intracardiac repair has largely replaced the staged approach.</p><p>Additional details about surgical repair are provided separately. (See  <a class="medical medical_review" href="/d/html/5770.html" rel="external">"Tetralogy of Fallot (TOF): Management and outcome", section on 'Surgical repair'</a>.)</p><p class="headingAnchor" id="H938185324"><span class="h2">Repair in adulthood</span><span class="headingEndMark"> — </span>Although it is now a rare occurrence, TOF remains the most common unrepaired cyanotic congenital heart disease defect in adults. Complete repair is feasible in adult patients and may result in improved function. However, there is an increased operative risk compared with younger patients.</p><p>Pulmonary valve replacement (PVR) is commonly required in adults undergoing TOF repair. Adults with unoperated TOF and prior palliative surgery commonly have severe RV hypertrophy and RV diastolic dysfunction and, therefore, tolerate severe pulmonary regurgitation poorly. Late repair can be complicated by previous palliative surgery as this increases operative complexity.</p><p>In a case series of 52 adult patients (≥40 years old) who underwent TOF repair between 1970 and 2007, procedures for repair included PVR (n = 10), transannular patch (n = 10), and native pulmonary valve preservation (n = 32) [<a href="#rid1">1</a>]. In the 10 patients who received a transannular patch, four required reoperation for PVR due to poorly tolerated pulmonary regurgitation. Approximately one-half of the patients in the series had had previous palliative surgery. Three patients died during the perioperative period, and during a mean follow-up of 15 years, 29 of the 49 remaining survivors died. The 10-year survival rate was lower compared with an age- and sex-matched population (73 versus 91 percent) and compared with patients with TOF operated on at a younger age who had an expected 20-year survival rate of 86 percent. Of the 49 survivors, 42 had improvement in their New York Heart Association functional class and only five patients remained in functional class III or IV  (<a class="graphic graphic_table graphicRef52683" href="/d/graphic/52683.html" rel="external">table 1</a>).</p><p>In two other case series of TOF repair in adulthood, intraoperative mortality was 2.5 percent and in-hospital mortality was 16 percent [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H1450359326"><span class="h1">LONG-TERM FOLLOW-UP</span><span class="headingEndMark"> — </span>Patients who have undergone surgical repair of TOF require long-term follow-up with a cardiologist with expertise in congenital heart disease. Patients are at risk for long-term complications after surgery, including chronic pulmonary regurgitation, RV dysfunction, residual RV outflow tract (RVOT) obstruction, aortic root and valve dilation, arrhythmias, and sudden cardiac death (SCD)  (<a class="graphic graphic_table graphicRef141992" href="/d/graphic/141992.html" rel="external">table 2</a>). (See <a class="local">'Long-term complications'</a> below.)</p><p>Care is focused on identifying, managing, and preventing these long-term sequelae.</p><p class="headingAnchor" id="H2667351079"><span class="h2">Routine visits</span><span class="headingEndMark"> — </span>Routine follow-up visits should occur at least annually, with a focused history, physical examination, and testing [<a href="#rid4">4,5</a>].</p><p>The history and physical examination focus on the patient's cardiac status, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Episodes of palpitations, dizziness, or syncope, which may suggest an underlying arrhythmia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms (eg, dyspnea or decreased exercise tolerance) and signs of heart failure (eg, jugular venous distension, pulmonary congestion, peripheral edema, and hepatomegaly), which may be caused by valve dysfunction, shunt lesions, arrhythmias, and/or left or right ventricular dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Murmurs on cardiac auscultation may suggest pulmonary, tricuspid, or aortic valve regurgitation, or pulmonary or branch pulmonary artery (PA) stenosis.</p><p></p><p class="headingAnchor" id="H3645217706"><span class="h2">Tests</span><span class="headingEndMark"> — </span>The following tests are performed routinely in patients who have undergone repair of TOF. The frequency of testing varies depending on the patient's age, type of repair, symptoms, or ongoing cardiac issues (such as arrhythmias, RV dilation, or RVOT obstruction) [<a href="#rid4">4,6</a>]  (<a class="graphic graphic_table graphicRef141991" href="/d/graphic/141991.html" rel="external">table 3</a>). Additional testing is performed as needed when new symptoms or signs develop.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echocardiography</strong> is recommended annually until the age of 10 years and every six months to two years through adulthood depending upon the patient's physiologic stage [<a href="#rid4">4,6</a>]. (See <a class="local">'Physiologic stage'</a> below.)</p><p></p><p class="bulletIndent1">The focus of echocardiography monitoring is to:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Detect the presence and size of any residual septal defects</p><p class="bulletIndent2"><span class="glyph">•</span>Determine the severity of pulmonary insufficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Determine if there is persistent RVOT obstruction, and if present, ascertain the severity and the site of obstruction</p><p class="bulletIndent2"><span class="glyph">•</span>Assess RV and left ventricular (LV) size, function, and wall motion</p><p class="bulletIndent2"><span class="glyph">•</span>Detect aortic root dilation and/or aortic valve insufficiency</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrocardiography (ECG) </strong>is performed at least once annually to assess cardiac rhythm and to evaluate QRS duration, which, if prolonged, is a risk factor for ventricular tachycardia (VT). (See <a class="local">'Arrhythmias and sudden cardiac death'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ambulatory ECG monitoring</strong> can be considered every one to two years for individuals with physiologic stage C or stage D. (See  <a class="medical medical_review" href="/d/html/958.html" rel="external">"Ambulatory ECG monitoring"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CMR</strong> – Advanced cardiac imaging, generally with cardiovascular magnetic resonance (CMR), is an essential component of the postoperative assessment of patients with TOF and is the gold standard for assessment of chamber sizes and ventricular performance. CMR is generally performed in adolescents and adults with repaired TOF every one to three years, depending on the clinical concerns [<a href="#rid4">4</a>]. Annual CMR is suggested for patients with any of the following findings [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate RV dilation (RV end diastolic dimension &gt;150 cc/m<sup>2</sup>)</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive RV dilation (increase of &gt;25 mL/m<sup>2</sup> between studies)</p><p class="bulletIndent2"><span class="glyph">•</span>RV dysfunction (RV ejection fraction [RVEF] &lt;38 percent or &gt;6 percent decrease in RVEF between studies)</p><p></p><p class="bulletIndent1">Measurements of RV size and performance are important in determining the need for and timing of pulmonary valve replacement (PVR). </p><p></p><p class="bulletIndent1">Assessment of all levels of the RVOT, including the branch PAs, is possible with CMR, allowing far more thorough evaluation than is possible with echocardiography. Quantitative assessment of flows to the left and right lungs may help guide surgical- and catheterization-based interventions. Evaluation of aortic size and regurgitant flow is also possible with this modality.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac CT</strong> – For patients in whom CMR is not an option (eg, due to an implanted CMR-incompatible pacemaker or implantable cardioverter-defibrillator [ICD]), cardiac computed tomography (CT) is performed to evaluate ventricular volumes and function. When using cardiac CT, the benefit of routine imaging is weighed against the risk of radiation exposure. (See  <a class="medical medical_review" href="/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging"</a>.)</p><p></p><p class="bulletIndent1">In addition, cardiac CT is preferred over CMR for patients who are being considered for PVR, since cardiac CT is required to evaluate candidacy for self-expanding transcatheter pulmonary valves (Harmony and Alterra). CT also provides important information for patients being considered for reoperation, including assessment of the coronary arteries and reentry planning. (See  <a class="medical medical_review" href="/d/html/86481.html" rel="external">"Transcatheter pulmonary valve implantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise testing</strong> provides an objective measurement of exercise capacity and may detect exertional arrhythmias. It is performed every three to four years in adolescents and adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac catheterization</strong> is performed in individuals when transcatheter intervention is being considered. Additional indications include assessment of hemodynamics to help guide therapy for patients with advanced heart failure or pulmonary hypertension and for those undergoing pretransplant evaluation. (See  <a class="medical medical_review" href="/d/html/105507.html" rel="external">"Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Preoperative coronary artery assessment with CT or angiography is routinely performed in adults undergoing evaluation for intervention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrophysiologic study</strong> with mapping is performed in patients who are at risk for VT. (See <a class="local">'Indications for EPS'</a> below.)</p><p></p><p class="headingAnchor" id="H2017340663"><span class="h2">Physiologic stage</span><span class="headingEndMark"> — </span>The physiologic stage is categorized as follows (patients are classified based upon the highest [most severe] relevant physiologic feature) [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage A</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New York Heart Association (NYHA) class I symptoms  (<a class="graphic graphic_table graphicRef52683" href="/d/graphic/52683.html" rel="external">table 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>No hemodynamic or anatomic sequelae</p><p class="bulletIndent2"><span class="glyph">•</span>No arrhythmias</p><p class="bulletIndent2"><span class="glyph">•</span>Normal exercise capacity</p><p class="bulletIndent2"><span class="glyph">•</span>Normal renal/hepatic/pulmonary function</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage B</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NYHA class II symptoms  (<a class="graphic graphic_table graphicRef52683" href="/d/graphic/52683.html" rel="external">table 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Mild hemodynamic sequelae (mild aortic enlargement, mild ventricular enlargement, mild ventricular dysfunction)</p><p class="bulletIndent2"><span class="glyph">•</span>Mild valvular disease</p><p class="bulletIndent2"><span class="glyph">•</span>Trivial or small shunt (not hemodynamically significant)</p><p class="bulletIndent2"><span class="glyph">•</span>Arrhythmia not requiring treatment</p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal objective cardiac limitation to exercise</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage C</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NYHA class III symptoms  (<a class="graphic graphic_table graphicRef52683" href="/d/graphic/52683.html" rel="external">table 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Significant (moderate or greater) valvular disease</p><p class="bulletIndent2"><span class="glyph">•</span>Moderate or greater ventricular dysfunction (systemic, pulmonic, or both)</p><p class="bulletIndent2"><span class="glyph">•</span>Moderate aortic enlargement</p><p class="bulletIndent2"><span class="glyph">•</span>Venous or arterial stenosis</p><p class="bulletIndent2"><span class="glyph">•</span>Mild or moderate hypoxemia/cyanosis</p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamically significant shunt</p><p class="bulletIndent2"><span class="glyph">•</span>Arrhythmias controlled with treatment</p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary hypertension (less than severe)</p><p class="bulletIndent2"><span class="glyph">•</span>End-organ dysfunction responsive to therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage D</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NYHA class IV symptoms  (<a class="graphic graphic_table graphicRef52683" href="/d/graphic/52683.html" rel="external">table 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Severe aortic enlargement</p><p class="bulletIndent2"><span class="glyph">•</span>Arrhythmias refractory to treatment</p><p class="bulletIndent2"><span class="glyph">•</span>Severe hypoxemia (almost always associated with cyanosis)</p><p class="bulletIndent2"><span class="glyph">•</span>Severe pulmonary hypertension</p><p class="bulletIndent2"><span class="glyph">•</span>Eisenmenger syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Refractory end-organ dysfunction</p><p></p><p class="headingAnchor" id="H3857989516"><span class="h1">LONG-TERM COMPLICATIONS</span><span class="headingEndMark"> — </span>Long-term complications after TOF repair include pulmonary regurgitation with associated RV enlargement, residual RV outflow tract (RVOT) obstruction, RV dysfunction, aortic root dilation and aortic valve insufficiency, arrhythmias including atrial tachycardia and VT, endocarditis, and SCD  (<a class="graphic graphic_table graphicRef141992" href="/d/graphic/141992.html" rel="external">table 2</a>) [<a href="#rid8">8-10</a>].</p><p>Long-term cardiovascular sequelae are common among adult survivors of TOF repair, and approximately one-third of patients require reoperation, most commonly for pulmonary valve replacement (PVR) [<a href="#rid10">10-12</a>]. Patients who have undergone repair with a transannular patch  (<a class="graphic graphic_figure graphicRef67062" href="/d/graphic/67062.html" rel="external">figure 2</a>) are at particularly high risk of needing reoperation [<a href="#rid8">8</a>]. (See <a class="local">'Pulmonary valve replacement (PVR)'</a> below.)</p><p class="headingAnchor" id="H77416515"><span class="h2">Chronic pulmonary regurgitation</span><span class="headingEndMark"> — </span>Intracardiac repair with a transannular RVOT patch results in obligate chronic severe pulmonary regurgitation. Pulmonary regurgitation may also occur in patients who have monocusp valves placed at the time of initial repair or who have a valved conduit from the RV to the pulmonary artery (PA) as these valves become progressively incompetent over time. The degree of regurgitation may vary depending on surgical approach and on the presence or absence of associated PA stenosis. Long-standing severe pulmonary regurgitation causes RV volume overload with often progressive RV enlargement [<a href="#rid13">13,14</a>]. This may be associated with increasing tricuspid regurgitation, further contributing to RV enlargement.</p><p>PVR is often necessary in patients with repaired TOF to restore pulmonary valve competence and improve RV function, as discussed in detail below. (See <a class="local">'Pulmonary valve replacement (PVR)'</a> below.)</p><p class="headingAnchor" id="H1138609167"><span class="h2">Right ventricular dysfunction</span><span class="headingEndMark"> — </span>Patients with repaired TOF are at risk for RV systolic and diastolic dysfunction [<a href="#rid15">15</a>]. Patients with RV volume and/or pressure overload are at risk for progressive adverse RV remodeling and RV dysfunction, associated with decreased exercise tolerance, right heart failure, and arrhythmias (ie, VT, SCD, atrial flutter, and atrial fibrillation). As discussed below, the goal of PVR is to improve RV remodeling before RV dysfunction and associated complications develop. (See <a class="local">'Pulmonary valve replacement (PVR)'</a> below.)</p><p class="headingAnchor" id="H2060127577"><span class="h2">Left ventricular dysfunction</span><span class="headingEndMark"> — </span>Patients with repaired TOF are also at risk for LV systolic and diastolic dysfunction [<a href="#rid15">15</a>]. The decline in RV function can also lead to LV dysfunction due to septal shift and ventricular/ventricular interaction [<a href="#rid13">13,16,17</a>].</p><p class="headingAnchor" id="H2935390226"><span class="h2">Residual RVOT obstruction</span><span class="headingEndMark"> — </span>Residual RVOT obstruction can persist after the original intracardiac operation due to hypertrophied subvalvar muscle, annular hypoplasia, pulmonary valve stenosis, supravalvar pulmonary stenosis, or branch PA stenosis (most commonly, left PA stenosis in the region of ductal insertion) [<a href="#rid18">18</a>]. Mild obstruction is usually well tolerated, but severe obstruction may require reoperation or catheter-based intervention (transcatheter pulmonary valve implantation [TPVI]). Relief of PA stenosis by balloon dilation or stenting may be necessary prior to PVR or TPVI [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/86481.html" rel="external">"Transcatheter pulmonary valve implantation", section on 'Conduit preparation and prestenting'</a>.)</p><p class="headingAnchor" id="H4199786063"><span class="h2">Aortic root dilation</span><span class="headingEndMark"> — </span>A substantial portion of adult TOF patients have ascending aorta dilation and are at risk for the development of aortic valve insufficiency over time [<a href="#rid20">20-22</a>]; there have been case reports of patients with aortic dissection, though these complications appear rare.</p><p>In two large case series, approximately 30 to 50 percent of adult patients with repaired TOF had ascending aorta dilation [<a href="#rid21">21,22</a>]. Moderate to severe aortic valve regurgitation was observed in 3.5 percent of patients [<a href="#rid22">22</a>]. Aortic valve repair or replacement was performed in 1 to 2 percent or patients and another 1 to 2 percent underwent aortic root replacement. No patients had aortic dissection and there were no deaths due to aortic disease.</p><p class="headingAnchor" id="H3697562869"><span class="h2">Endocarditis</span><span class="headingEndMark"> — </span>Patients with repaired TOF are at increased risk of infective endocarditis (IE) [<a href="#rid23">23</a>]. Factors predisposing to IE among patients with repaired TOF include the presence of a prosthetic valve as well as the presence of residual defects at or adjacent to the site of prosthetic material. Among patients with surgical or transcatheter bioprosthetic pulmonary valves, the risk of endocarditis is highest among those with bovine jugular vein valves. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/86481.html" rel="external">"Transcatheter pulmonary valve implantation", section on 'Endocarditis'</a>.)</p><p>Measures to prevent IE are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p class="headingAnchor" id="H1996600256"><span class="h2">Arrhythmias and sudden cardiac death</span><span class="headingEndMark"> — </span>Following surgical repair for TOF, patients are at risk of atrial tachyarrhythmias (ATs), ventricular arrhythmias, and SCD [<a href="#rid6">6,24</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrial tachyarrhythmias</strong> – The prevalence of ATs among adult patients with repaired TOF is approximately 20 percent; the risk increases considerably after age 45 years [<a href="#rid25">25,26</a>]. Initially, typical and atypical atrial flutter predominate; later, atrial fibrillation becomes increasingly prevalent.</p><p></p><p class="bulletIndent1">Of note, because the ECG typically demonstrates a right bundle branch block pattern following TOF repair, most ATs in these patients are wide complex (with right bundle branch block) regardless of their specific mechanism.</p><p></p><p class="bulletIndent1">Risk factors for ATs include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For any AT – Increasing number of cardiac operations [<a href="#rid25">25</a>] and older age at repair [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Atrial fibrillation/flutter – Left atrial dilation, lower LV ejection fraction, and tricuspid regurgitation [<a href="#rid24">24,25</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intraatrial reentrant tachycardia – Right atrial enlargement and hypertension [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">Additional details about the risk of ATs in the adult CHD population are provided separately. (See  <a class="medical medical_review" href="/d/html/13599.html" rel="external">"Atrial arrhythmias (including AV block) in congenital heart disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventricular tachycardia</strong> – The prevalence of ventricular arrhythmias among adult patients with repaired TOF is approximately 15 percent [<a href="#rid25">25,26</a>].</p><p></p><p class="bulletIndent1">Risk factors for VT in this population include increasing number of cardiac operations [<a href="#rid25">25</a>], LV systolic and diastolic dysfunction [<a href="#rid25">25</a>], pulmonary regurgitation [<a href="#rid24">24,27</a>], prolonged QRS duration [<a href="#rid24">24,25</a>], and older age at repair [<a href="#rid2">2,3</a>]. The risk of VT generally increases over time.</p><p></p><p class="bulletIndent1">VT may display a typical left bundle branch block pattern since it generally originates from the RV. However, VT can originate from one of several potential anatomic isthmuses within the RV and, depending on the direction of conduction through the critical isthmus, a right bundle branch block pattern can sometimes be seen despite origin in the RV [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">Monomorphic VT in TOF is usually dependent upon slow conduction within one of these isthmuses, identifiable either by direct activation mapping during VT or characterization of conduction properties within the isthmus. By this approach, VT can be amenable to radiofrequency catheter ablation or intraoperative cryoablation. However, the isthmus may not be reliably associated with the ventriculotomy scar itself, so preoperative mapping is warranted to define the precise VT substrate [<a href="#rid29">29</a>]. Indications for electrophysiologic study (EPS) and ablation are discussed in greater detail below. (See <a class="local">'Indications for EPS'</a> below and <a class="local">'Ablation'</a> below.)</p><p></p><p class="bulletIndent1">Although pulmonary valve regurgitation and RV dilation are associated with VT, the risk of VT is not eliminated with PVR [<a href="#rid30">30,31</a>]. Because transcatheter PVR may limit later access to potential ablation sites, many centers (including our own) perform EPS prior to PVR, as discussed below. (See <a class="local">'Indications for EPS'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sudden cardiac death</strong> – The risk of SCD in adults with repaired TOF is approximately 2 to 7 percent over 10 years [<a href="#rid24">24,32-35</a>]. In a study that included 869 adult patients with repaired TOF who were followed for a median of nine years, SCD occurred in 6 percent (and annual risk of 0.7 percent per year) [<a href="#rid34">34</a>]. The majority of SCD is presumed to be due to ventricular arrhythmia [<a href="#rid36">36-38</a>].</p><p></p><p class="bulletIndent1">In addition to inducible VT on EPS, other reported risk factors for SCD and/or VT include [<a href="#rid4">4,39-41</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prolonged QRS (eg, QRS duration &gt;180 ms)</p><p class="bulletIndent2"><span class="glyph">•</span>Older age at the time of repair</p><p class="bulletIndent2"><span class="glyph">•</span>Previous palliative shunt</p><p class="bulletIndent2"><span class="glyph">•</span>Higher number of thoracotomies</p><p class="bulletIndent2"><span class="glyph">•</span>RV dilation</p><p class="bulletIndent2"><span class="glyph">•</span>Ventricular dysfunction</p><p class="bulletIndent2"><span class="glyph">•</span>History of atrial arrhythmias</p><p></p><p class="headingAnchor" id="H3368321073"><span class="h1">LONG-TERM MANAGEMENT ISSUES</span></p><p class="headingAnchor" id="H230898069"><span class="h2">Pulmonary valve replacement (PVR)</span><span class="headingEndMark"> — </span>PVR is often necessary in patients with repaired TOF to restore pulmonary valve competence and improve RV function [<a href="#rid42">42-46</a>].</p><p class="headingAnchor" id="H768047792"><span class="h3">Indications</span><span class="headingEndMark"> — </span>The optimal criteria for PVR in patients with repaired TOF are uncertain; various criteria have been proposed  (<a class="graphic graphic_table graphicRef142975" href="/d/graphic/142975.html" rel="external">table 4</a>) [<a href="#rid4">4,5,47,48</a>]. Most experts agree that PVR is indicated in patients with moderate or severe pulmonary regurgitation (typically defined as regurgitant fraction &gt;25 percent on CMR imaging) associated with any of the following [<a href="#rid4">4,5,48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular symptoms that are not otherwise explained.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RV enlargement (typically defined by quantitative CMR measurements, including RV end-diastolic volume index [RVEDVi] ≥160 mL/m<sup>2</sup> and/or RV end-systolic volume index [RVESVi] ≥80 mL/m<sup>2</sup>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RV systolic dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced exercise capacity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ventricular arrhythmias attributable to the right heart enlargement/dysfunction from pulmonary regurgitation.</p><p></p><p>However, the specific thresholds vary somewhat between different resources, as highlighted in the table  (<a class="graphic graphic_table graphicRef142975" href="/d/graphic/142975.html" rel="external">table 4</a>). Ideally, PVR should be performed before RV dysfunction develops.</p><p>The evidence supporting use of these parameters and thresholds in determining the timing of PVR comes from observational studies of patients with repaired TOF who did or did not undergo PVR [<a href="#rid46">46,47,49-55</a>]. In a retrospective study from the INDICATOR database that included 1143 patients with repaired TOF who had CMR RV volumetric data available, 540 patients (47 percent) underwent PVR at a median of four months after CMR [<a href="#rid47">47</a>]. During median follow-up of eight years, 5 percent of the cohort died and 2 percent experienced resuscitated cardiac arrest or sustained VT. In a propensity score adjusted analysis, PVR was associated with lower risk of death, cardiac arrest, or sustained VT (hazard ratio 0.41, 95% CI 0.21-0.81). In a subgroup analysis exploring the effect of PVR in patients who did versus did not meet explicit criteria (as detailed in the first two columns of the table  (<a class="graphic graphic_table graphicRef142975" href="/d/graphic/142975.html" rel="external">table 4</a>)), PVR was associated with lower risk of adverse outcome among patients who met criteria but not among those who did not meet criteria.</p><p>Following PVR, RV volumes decrease even in those with marked RV dilation [<a href="#rid46">46,51-54</a>]. However, patients with RVEDVi &gt;160 to 170 mL/m<sup>2</sup> or RVESVi &gt;80 to 85 mL/m<sup>2</sup> are unlikely to achieve restoration of normal RV volume [<a href="#rid49">49,51-53</a>]. A meta-analysis including 48 studies with a total of 3118 patients found that while greater pre-PVR RVEDVi was associated with greater reductions in RVEDVi and RVESVi post-PVR, greater pre-PVR RVEDVi was associated with lesser improvement in symptoms and functional class post-PVR [<a href="#rid46">46</a>].</p><p>Although aerobic exercise capacity typically improves substantially after PVR, studies have shown that patients who undergo PVR late in the disease process do not demonstrate improvement in RV function and exercise capacity [<a href="#rid55">55,56</a>]. A study of 25 adults with TOF undergoing PVR found that preoperative RVEF &lt;40 percent was associated with reduced likelihood (13 versus 50 percent) of attaining an RVEF ≥40 percent at a mean of 28 months post PVR [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H3390747413"><span class="h3">Pre-PVR evaluation</span><span class="headingEndMark"> — </span>For patients who meet criteria for PVR, preprocedural evaluation generally includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Imaging with echocardiography, CMR, and/or cardiac CT. Preprocedural imaging with cardiac CT is required to evaluate candidacy for self-expanding transcatheter pulmonary valves (Harmony and Alterra). (See  <a class="medical medical_review" href="/d/html/86481.html" rel="external">"Transcatheter pulmonary valve implantation", section on 'TPV devices'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrophysiologic study (EPS). (See <a class="local">'Patients undergoing PVR'</a> below.)</p><p></p><p class="headingAnchor" id="H3000069114"><span class="h3">Surgical PVR</span><span class="headingEndMark"> — </span>Outcomes following surgical PVR in patients with repaired TOF are discussed below. (See <a class="local">'Comparative data'</a> below.)</p><p>Additional details about surgical PVR are provided separately. (See  <a class="medical medical_review" href="/d/html/104752.html" rel="external">"Pulmonic regurgitation", section on 'Surgical'</a>.)</p><p class="headingAnchor" id="H3417032454"><span class="h3">Transcatheter PVI (TPVI)</span><span class="headingEndMark"> — </span>TPVI is an alternative to surgical PVR that is used in right ventricular to pulmonary artery conduits or native right ventricular outflow tracts (RVOT) with severe RVOT obstruction or severe pulmonary regurgitation [<a href="#rid57">57-61</a>]. Data comparing surgical PVR and TPVI in patients with repaired TOF are discussed below. (See <a class="local">'Comparative data'</a> below.)</p><p>Additional details regarding TPVR, including approved devices, complications (including risk of endocarditis), and need for reintervention, are discussed separately. (See  <a class="medical medical_review" href="/d/html/86481.html" rel="external">"Transcatheter pulmonary valve implantation"</a>.)</p><p class="headingAnchor" id="H3977232816"><span class="h3">Comparative data</span><span class="headingEndMark"> — </span>Data directly comparing surgical PVR with TPVR in patients with TOF are limited to observational (mostly retrospective) studies [<a href="#rid62">62-64</a>]. Based on the available reports, long-term outcomes appear to be comparable.</p><p>In a meta-analysis of 11 observational studies (4364 patients), TPVR was associated with lower in-hospital mortality and shorter duration of hospitalization compared with surgical PVR, but reintervention rates and risk of infective endocarditis (IE) were higher with TPVR [<a href="#rid64">64</a>]. However, patients with repaired TOF accounted for only a subset of the study population in these studies, as many patients had other causes of pulmonary valve disease. In a multicenter retrospective study limited to patients with repaired TOF who underwent TPVR (n = 191) or surgical PVR (n = 382) from 2010 through 2016, in-hospital mortality was similar in both groups (1 percent each) as was the rate of procedure-related complications; however, hospital length of stay was shorter in the TPVR group (median one versus five days) [<a href="#rid62">62</a>].</p><p>Long-term outcomes after surgical and TPVR appear to be generally comparable:</p><p class="bulletIndent1"><span class="glyph">●</span>Outcomes after surgical PVR – In a meta-analysis of 15 observational studies including 2765 patients with TOF, overall survival following surgical PVR was 97 percent at five years and 94 percent at 10 years of follow-up [<a href="#rid54">54</a>]. Reintervention rates at five and 10 years were approximately 4 and 17 percent, respectively [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Outcomes after TPVR – In a large multicenter study of 2476 patients who underwent TPVR (the underlying diagnosis was TOF in 55 percent), survival at eight years after the procedure was 91.1 percent [<a href="#rid65">65</a>]. Independent risk factors for mortality identified through multivariable analysis included age at the time of TPVR, concomitant prosthetic valve in another position, and presence of a transvenous pacemaker/defibrillator. The reintervention rate at eight years was 25 percent [<a href="#rid65">65</a>].</p><p></p><p>With both procedures, degeneration of the valve tissue can be expected over time. CMR data evaluating patients with repaired TOF who have undergone surgical PVR or TPVR demonstrated that the favorable RV remodeling noted initially after valve replacement deteriorated over 7 to 10 years in many of the patients, due to deterioration of the prosthesis [<a href="#rid66">66</a>]. Measures of RV size and function at 7 to 10 years after PVR were similar to pre-replacement values, highlighting again the need for referral for valve replacement before the evolution of marked RV dilation and before deterioration of RV performance. Though it was encouraging that 69 percent of patients were shown to have low RV pressure and volume loads 7 to 10 years after PVR, these data emphasize the need for continued surveillance of RV size and function post-PVR [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H1236672515"><span class="h3">Mechanical PVR</span><span class="headingEndMark"> — </span>Mechanical PVR is rarely performed but may be considered in patients with mechanical valve prostheses in another valve position, need for chronic <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation, or multiple prior operative interventions. Mechanical prosthetic valves appear to be safe in this population [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H4177670187"><span class="h2">Management of VT and prevention of SCD</span><span class="headingEndMark"> — </span>VT and SCD are important causes of mortality after intracardiac repair of TOF. Identifying patients at risk for VT and SCD and providing an effective intervention (eg, ablation or ICD implantation) could reduce long-term mortality. However, a reliable risk stratification schema is lacking in this patient population.</p><p class="headingAnchor" id="H4025575440"><span class="h3">Indications for EPS</span><span class="headingEndMark"> — </span>EPS with programmed ventricular stimulation aids in the assessment for VT risk in patients with TOF and may be combined with radiofrequency ablation when a suitable VT substrate is identified.</p><p class="headingAnchor" id="H1124743019"><span class="h4">Individual risk factors</span><span class="headingEndMark"> — </span>EPS with ventricular stimulation is appropriate for patients with repaired TOF with one or more of the following symptoms of VT or risk factors for SCD or inducible VT:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms that may be caused by VT include unexplained syncope and sustained palpitations [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VT (symptomatic or asymptomatic) [<a href="#rid4">4</a>]. This includes recurrent VT resulting in repeated ICD shocks in patients with repaired TOF in whom EPS may identify a potential site for ablation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some clinicians include RV dysfunction and extensive RV scarring as risk factors for VT that should prompt EPS [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>QRS duration ≥180 ms is a longstanding criterion [<a href="#rid4">4,24</a>], although a later report found that QRS fragmentation was a superior predictor of mortality in patients with TOF [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with TOF undergoing EPS and catheter ablation for atrial arrhythmias. In these patients, programmed ventricular stimulation to assess for susceptibility to VT is reasonable since risk factors are similar for both arrhythmias in this population and a history of atrial arrhythmias is a risk factor for inducible VT [<a href="#rid49">49</a>].</p><p></p><p>In a multicenter study of 252 patients with repaired TOF who underwent EPS with ventricular stimulation, sustained monomorphic VT and polymorphic VT were observed in 30 and 4 percent of patients, respectively [<a href="#rid71">71</a>]. After adjusting for other factors, inducible VT remained a strong predictor for future clinical VT or SCD. Its predictive value was greater in patients with underlying risk factors for VT compared with those without risks (positive predictive value 68 versus 25 percent and negative predictive value 86 versus 99 percent, respectively).</p><p>Limited data suggest that CMR findings may correlate with electroanatomic mapping [<a href="#rid72">72,73</a>]. However, the ability of this methodology to reliably predict VT is uncertain. Thus, invasive EPS with electroanatomic mapping and assessment of the conduction isthmuses remain essential in evaluation of the VT substrate.</p><p class="headingAnchor" id="H3252289080"><span class="h4">SCD risk scores</span><span class="headingEndMark"> — </span>Some centers use the PREVENTION-ACHD risk score to identify adults with congenital heart disease (ACHD, including those with TOF) at risk for SCD [<a href="#rid74">74,75</a>]. The PREVENTION-ACHD risk score model estimates risk of SCD by assigning one point to each of the following risk factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary artery disease</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure symptoms (New York Heart Association [NYHA] class II or III)</p><p class="bulletIndent1"><span class="glyph">●</span>Supraventricular tachycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic ventricular systolic dysfunction (LVEF &lt;40 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired subpulmonic ventricular function (RVEF &lt;40 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>QRS duration ≥ 120 ms</p><p class="bulletIndent1"><span class="glyph">●</span>QT dispersion ≥70 ms</p><p></p><p>For adults with TOF, the presence of ≥3 risk factors is associated with an annual risk of SCD of 3 to 4 percent [<a href="#rid75">75,76</a>]. A study including 783 patients with ACHD (18 percent with TOF), the risk score model had a sensitivity of 50 percent and a specificity of 93 percent for SCD or VT/ventricular fibrillation in two years [<a href="#rid75">75</a>]. The risk score model was more sensitive than ICD indications in the 2014 Pediatric and Congenital Electrophysiology Society/Heart Rhythm Society expert consensus statement on arrhythmias in ACHD (which had sensitivity of 25 percent and specificity of 98 percent) [<a href="#rid69">69,75</a>].</p><p class="headingAnchor" id="H3107684315"><span class="h4">Patients undergoing PVR</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prior to PVR</strong> – At many centers, including ours, EPS is performed in all patients undergoing PVR [<a href="#rid49">49,74,77,78</a>]. However, this practice is not standardized, and some centers perform EPS only in selected patients with TOF prior to PVR. Performing EPS prior to the PVR procedure may identify the responsible substrate, which can then be addressed either with radiofrequency ablation at the time of EPS or with intraoperative cryoablation at the time of surgery [<a href="#rid30">30</a>]. This approach is consistent with the European Society of Cardiology guidelines for management of ACHD [<a href="#rid5">5</a>]. The utility of this approach is debated but favored in many institutions experienced with VT ablation in this population. The rationale is based on the concern that the structural support of the prosthetic valve may block access to important anatomic isthmuses in the event of future VT.</p><p></p><p class="bulletIndent1">A prospective multicenter study enrolled 120 patients with TOF who underwent EPS with programmed ventricular stimulation prior to PVR [<a href="#rid49">49</a>]. When the critical isthmus was identified, it was most commonly (90 percent) located between the ventricular septal defect patch and pulmonary annulus. The independent predictors of inducible VT were history of atrial arrhythmia and pulmonary annulus diameter &gt;26 mm. EPS led to a change in management in 23 cases (19.2 percent): 18 underwent catheter ablation, three surgical cryoablation during PVR, and nine ICD implantation. Repeat PVR at a mean of five months after PVR was negative in eight of nine patients. No patient experienced sustained ventricular arrhythmia during 13 months of follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-PVR</strong> – For patients known to have VT prior to PVR or considered to be at high risk based upon a positive EPS, EPS testing should be repeated after PVR. If there is persistence of inducible VT, management options include radiofrequency ablation and/or placement of an ICD [<a href="#rid79">79</a>]. (See <a class="local">'Ablation'</a> below and <a class="local">'ICD placement'</a> below.)</p><p></p><p class="headingAnchor" id="H778457311"><span class="h3">Ablation</span><span class="headingEndMark"> — </span>When a defined substrate can be targeted, catheter or surgical ablation is a reasonable treatment option [<a href="#rid4">4,30,80-85</a>]. As an example, in a study of 47 patients with TOF undergoing ICD for secondary prevention of VT, 43 percent of patients had VT ablation performed prior to ICD implantation, including transcatheter ablation in 12 patients and surgical cryoablation at the time of PVR in eight patients [<a href="#rid86">86</a>]. Over median follow-up of 6.7 years, patients who had undergone prior ablation were less likely to receive appropriate ICD shocks compared with those who had not (10 versus 37 percent, respectively).</p><p>Follow-up EPS should be considered in patients undergoing catheter ablation or surgical ablation.</p><p class="headingAnchor" id="H910583930"><span class="h4">Catheter ablation</span><span class="headingEndMark"> — </span>The role of EPS guided catheter ablation was illustrated by a study of 78 patients with TOF who underwent EPS with ventricular stimulation and electroanatomic mapping, slowly conducting anatomic isthmuses were found in 92 percent of patients with inducible VT compared with only 4 percent of those without inducible VT [<a href="#rid81">81</a>]. However, QRS duration was similar in patients with and without inducible VT. Catheter ablation is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1007.html" rel="external">"Overview of catheter ablation of cardiac arrhythmias"</a>.)</p><p class="headingAnchor" id="H1311838658"><span class="h4">Intraoperative cryoablation</span><span class="headingEndMark"> — </span>For patients undergoing surgical PVR, cryoablation of identifiable isthmuses can be performed intraoperatively. The additional risk associated with adding this procedure to PVR surgery is modest and it has the benefit of preemptively eliminating these areas of abnormal conduction that predispose to VT [<a href="#rid30">30,85</a>]. Preoperative mapping is generally warranted to define the precise VT substrate since the isthmus may not be reliably associated with the ventriculotomy scar itself [<a href="#rid29">29</a>]. (See <a class="local">'Indications for EPS'</a> above.)</p><p>In a cohort of 205 adult patients undergoing PVR, surgical cryoablation was performed in 22 patients based upon risk factors or prior VT [<a href="#rid30">30</a>]. Over a median follow-up of 6.7 years, VT or SCD occurred in 10 percent of patients who did not undergo cryoablation compared with 5 percent (1 of 22) of patients who underwent cryoablation.</p><p class="headingAnchor" id="H1138923863"><span class="h3">ICD placement</span><span class="headingEndMark"> — </span>Standard recommendations for ICD placement apply to patients at high risk for ventricular arrhythmias, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary prevention for those with documented sustained VT, ventricular fibrillation or prior episode of resuscitated SCD (See  <a class="medical medical_review" href="/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary prevention for those with heart failure (NYHA functional class II or higher) and LVEF ≤35 percent on optimized medical therapy. (See  <a class="medical medical_review" href="/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a>.)</p><p></p><p class="bulletIndent1">For patients with repaired TOF and inducible sustained VT that is hemodynamically unstable or otherwise not amenable to ablation, we suggest ICD implantation [<a href="#rid4">4,87-89</a>].</p><p></p><p class="bulletIndent1">Indications for EPS are discussed above. (See <a class="local">'Indications for EPS'</a> above.)</p><p></p><p>Outcomes following ICD placement were described in two retrospective studies including a total of 286 adult patients with TOF who underwent ICD implantation for either primary or secondary prevention [<a href="#rid87">87,90</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>During median follow-up of four to seven years, approximately 30 to 40 percent of patients received at least one appropriate and effective ICD discharge. The rate was slightly lower in patients who had the ICD placed for primary compared with secondary prevention (7 to 8 percent per year versus 10 to 12 percent per year, respectively). Factors associated with increased likelihood of receiving appropriate ICD discharges included higher number of SCD risk factors, elevated LV end-diastolic pressure, nonsustained VT, and QRS fragmentation on ECG.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 30 to 40 percent of patients experienced at least one ICD-associated complication, including periprocedural complications (5 to 6 percent); inappropriate shocks (20 to 25 percent); lead-related complications (20 percent); and generator-related complications such as pocket infection, pain, or malfunction (6 to 10 percent). There were four arrhythmic deaths (1.4 percent), and three additional patients died due to SCD without tachyarrhythmias detected on ICD interrogation (presumed to be due to electromechanical dissociation).</p><p></p><p class="headingAnchor" id="H4068891931"><span class="h2">Prevention of endocarditis</span><span class="headingEndMark"> — </span>To reduce the risk of endocarditis, patients with TOF should maintain oral hygiene and receive timely treatment of infections. Patients with TOF may require antibiotic prophylaxis before certain dental or oral procedures to reduce the risk of IE. Antibiotic prophylaxis is recommended during the first six months after the corrective surgery or device or stent implantation. Prophylactic therapy is also recommended in patients who have prosthetic heart valves or if there are residual defects at the site or adjacent to the site of a prosthetic device or material. The approach to determining the need for prophylaxis is summarized in the figure  (<a class="graphic graphic_algorithm graphicRef140120" href="/d/graphic/140120.html" rel="external">algorithm 1</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p class="headingAnchor" id="H531614310"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>Pregnancy is not recommended in patients with unrepaired TOF [<a href="#rid4">4</a>]. For individuals with repaired TOF who do not have severe hemodynamic abnormalities, pregnancy outcomes are generally good [<a href="#rid26">26,91-94</a>]. A comprehensive cardiovascular evaluation by a congenital cardiac specialist is recommended prior to pregnancy to confirm there are no cardiovascular findings that should be treated before a pregnancy, or to suggest a pregnancy would be high risk and not advised.</p><p>A literature review of studies published between 1985 and 2007 evaluated the rates of complications during completed pregnancies among women with repaired TOF [<a href="#rid95">95</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Maternal complications included arrhythmias in 13 of 204 pregnancies (6.4 percent) and heart failure in 5 of 211 pregnancies (2.4 percent). There were no cases of myocardial infarction, stroke, or cardiovascular mortality in 222 pregnancies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fetal complications included premature delivery in 11 of 174 pregnancies (6.3 percent), fetal mortality in 1 of 222 pregnancies (0.5 percent), perinatal mortality in 3 of 222 pregnancies (1.4 percent), small for gestational age in 19 of 211 pregnancies (9 percent), and recurrent congenital heart disease (CHD) of any type in 6 of 202 pregnancies (3 percent).</p><p></p><p>In addition, offspring are more likely to have congenital anomalies and genetic mutations, especially 22q11.2 microdeletion, compared with the general population [<a href="#rid4">4</a>]. Approximately 15 percent of patients with TOF and other conotruncal defects have chromosome 22q11.2 microdeletion [<a href="#rid96">96</a>]. Screening for 22q11.2 microdeletion should be considered in patients with conotruncal abnormalities prior to pregnancy in order to provide appropriate genetic counseling. In the absence of 22q11.2 deletion, the risk of a fetus having CHD is approximately 4 to 6 percent. In contrast, children born to a parent with 22q11.2 microdeletion have a 50 percent chance of having the deletion and its associated complications. (See  <a class="medical medical_review" href="/d/html/83396.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis", section on 'Cardiac anomalies'</a>.)</p><p>Because of the increased risk of congenital anomalies, fetal echocardiography should be offered to the mother in the second trimester [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/6755.html" rel="external">"Congenital heart disease: Prenatal screening, diagnosis, and management", section on 'Advanced fetal cardiac evaluation'</a>.)</p><p>The general care for a pregnant woman with CHD is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles"</a>.)</p><p class="headingAnchor" id="H2712610598"><span class="h1">SPORTS PARTICIPATION</span><span class="headingEndMark"> — </span>The 2015 scientific statement of the American Heart Association and American College of Cardiology provides competitive athletic participation guidelines for patients with congenital heart disease (CHD), including TOF [<a href="#rid80">80</a>]. Of note, because of the paucity of evidence regarding physical activity in patients with TOF, these guidelines were based largely on consensus opinions of conference participants. We concur with these recommendations but stress that, as with any guidelines, recommendations need to be tailored to the patient and a comprehensive evaluation by an experienced clinician is required.</p><p class="bulletIndent1"><span class="glyph">●</span>Before participation in competitive sports, patients with TOF (repaired or unrepaired) should undergo evaluation, including clinical assessment, ECG, imaging assessment of ventricular function (typically with echocardiogram), and exercise testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with unrepaired TOF who are clinically stable and without clinical symptoms of heart failure may be considered for participation in only low-intensity class IA sports  (<a class="graphic graphic_figure graphicRef105651" href="/d/graphic/105651.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with repaired TOF may be considered for participation in moderate- to high-intensity sports  (<a class="graphic graphic_figure graphicRef105651" href="/d/graphic/105651.html" rel="external">figure 3</a>) if they do not have evidence of clinically significant right or left ventricular dysfunction (ejection fraction &gt;50 percent), arrhythmias, or outflow tract obstruction. To meet these criteria, the patient must be able to complete an exercise test without evidence of exercise-induced arrhythmias, hypotension, ischemia, or other concerning clinical symptoms. (See  <a class="medical medical_review" href="/d/html/95296.html" rel="external">"Physical activity and exercise in patients with congenital heart disease", section on 'Cardiopulmonary exercise testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with repaired TOF who have severe ventricular dysfunction (EF &lt;40 percent), severe outflow tract obstruction, or recurrent or uncontrolled atrial or ventricular arrhythmias should be restricted from all competitive sports.</p><p></p><p>Physical activity and exercise in patients with CHD are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/95296.html" rel="external">"Physical activity and exercise in patients with congenital heart disease"</a>.)</p><p class="headingAnchor" id="H1678460616"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/122280.html" rel="external">"Society guideline links: Congenital heart disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115414.html" rel="external">"Society guideline links: Congenital heart disease in infants and children"</a>.)</p><p class="headingAnchor" id="H2676064635"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient <sup>ed</sup>ucatio<sup>n </sup>articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient education” and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83995.html" rel="external">"Patient education: Tetralogy of Fallot (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H531541520"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical repair</strong> – In the modern era, most patients with tetralogy of Fallot (TOF)  (<a class="graphic graphic_figure graphicRef82493" href="/d/graphic/82493.html" rel="external">figure 1</a>) undergo primary intracardiac repair in infancy  (<a class="graphic graphic_figure graphicRef67062" href="/d/graphic/67062.html" rel="external">figure 2</a>). Although it is now a rare occurrence, TOF remains the most common cyanotic congenital heart disease (CHD) defect to reach adulthood without surgical repair. Complete repair is feasible in adult patients and may result in improved function. However, operative risk is high. (See <a class="local">'Surgical repair'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term follow-up </strong>– Patient who have undergone surgical repair of TOF require long-term follow-up with a cardiologist with expertise in CHD. Routine follow-up visits should occur at least annually, with a focused history, physical examination, and cardiac testing at regular intervals, as summarized in the table  (<a class="graphic graphic_table graphicRef141992" href="/d/graphic/141992.html" rel="external">table 2</a>). (See <a class="local">'Long-term follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term complications</strong> – Patients who have undergone intracardiac repair for TOF are at risk for chronic postoperative complications, including  (<a class="graphic graphic_table graphicRef141992" href="/d/graphic/141992.html" rel="external">table 2</a>) (see <a class="local">'Long-term complications'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary regurgitation with associated right ventricular (RV) enlargement (see <a class="local">'Chronic pulmonary regurgitation'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Residual RV outflow tract (RVOT) obstruction (see <a class="local">'Residual RVOT obstruction'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>RV dysfunction (see <a class="local">'Right ventricular dysfunction'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Aortic root dilation (see <a class="local">'Aortic root dilation'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Infective endocarditis (IE) (see <a class="local">'Endocarditis'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Arrhythmias, including atrial tachyarrhythmias (ATs), ventricular tachycardia (VT), and sudden cardiac death (SCD) (see <a class="local">'Arrhythmias and sudden cardiac death'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term management issues</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulmonary valve replacement (PVR)</strong> – PVR is often necessary in patients with repaired TOF to restore pulmonary valve competence and improve RV function. Ideally, PVR is performed before severe RV dysfunction develops; however, the optimal timing remains uncertain. We suggest PVR in patients with moderate or severe pulmonary regurgitation associated with any of the following (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'Indications'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cardiovascular symptoms that are not otherwise explained</p><p class="bulletIndent3"><span class="glyph">-</span>RV enlargement </p><p class="bulletIndent3"><span class="glyph">-</span>RV systolic dysfunction</p><p class="bulletIndent3"><span class="glyph">-</span>Reduced exercise capacity</p><p class="bulletIndent3"><span class="glyph">-</span>Ventricular arrhythmias attributable to the right heart enlargement/dysfunction from pulmonary regurgitation</p><p></p><p class="bulletIndent2">Specific thresholds used to define these criteria are detailed in the table  (<a class="graphic graphic_table graphicRef142975" href="/d/graphic/142975.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2">PVR can be performed surgically or with a transcatheter procedure (TPVR). Long-term outcomes appear to be comparable with both procedures. (See <a class="local">'Surgical PVR'</a> above and <a class="local">'Transcatheter PVI (TPVI)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of arrhythmias and prevention of SCD</strong> – Arrhythmias and SCD are important causes of mortality after intracardiac repair of TOF.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Atrial arrhythmias</strong> – Management of atrial arrhythmias is discussed separately. (See  <a class="medical medical_review" href="/d/html/13599.html" rel="external">"Atrial arrhythmias (including AV block) in congenital heart disease", section on 'Management'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>VT</strong> – Patients with documented VT or with risk factors for VT should undergo electrophysiology study (EPS) with ventricular stimulation. If a defined substrate is identified, we suggest catheter ablation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternatively, for patients undergoing surgical PVR, cryoablation of identifiable isthmuses can be performed intraoperatively. (See <a class="local">'Indications for EPS'</a> above and <a class="local">'Catheter ablation'</a> above and <a class="local">'Intraoperative cryoablation'</a> above.)</p><p></p><p class="bulletIndent3">Standard recommendations for implantable cardioverter-defibrillator (ICD) placement apply to patients at high risk for ventricular arrhythmias, including secondary prevention for those with documented sustained VT, ventricular fibrillation, or prior episode of resuscitated SCD and primary prevention for those with symptomatic ventricular dysfunction (left ventricular ejection fraction [LVEF] ≤35 percent). This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a> and  <a class="medical medical_review" href="/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a>.)</p><p></p><p class="bulletIndent3">For patients with TOF and inducible sustained VT that is hemodynamically unstable or otherwise not amenable to ablation, we suggest ICD implantation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endocarditis prophylaxis</strong> – Patients with TOF may require antibiotic prophylaxis before certain dental or oral procedures to reduce the risk of IE. The approach to determining the need for prophylaxis is summarized in the figure  (<a class="graphic graphic_algorithm graphicRef140120" href="/d/graphic/140120.html" rel="external">algorithm 1</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy </strong>– When possible, patients with TOF should have a comprehensive cardiovascular evaluation by a congenital cardiac specialist before pregnancy to confirm there are no cardiovascular findings that should be addressed before a pregnancy, or to suggest a pregnancy would be high risk and not advised. For individuals with repaired TOF who lack severe hemodynamic abnormalities, pregnancy outcomes are generally good for both the mother and infant. (See <a class="local">'Pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sports participation</strong> – Recommendations regarding participation in competitive sports should be tailored to the individual and informed by a comprehensive evaluation by an experienced clinician. (See <a class="local">'Sports participation'</a> above and  <a class="medical medical_review" href="/d/html/95296.html" rel="external">"Physical activity and exercise in patients with congenital heart disease"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Attenhofer Jost CH, Connolly HM, Burkhart HM, et al. Tetralogy of fallot repair in patients 40 years or older. Mayo Clin Proc 2010; 85:1090.</a></li><li><a class="nounderline abstract_t">Presbitero P, Demarie D, Aruta E, et al. Results of total correction of tetralogy of Fallot performed in adults. Ann Thorac Surg 1988; 46:297.</a></li><li><a class="nounderline abstract_t">Dittrich S, Vogel M, Dähnert I, et al. Surgical repair of tetralogy of Fallot in adults today. Clin Cardiol 1999; 22:460.</a></li><li><a class="nounderline abstract_t">Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:e698.</a></li><li><a class="nounderline abstract_t">Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021; 42:563.</a></li><li><a class="nounderline abstract_t">Krieger EV, Zeppenfeld K, DeWitt ES, et al. Arrhythmias in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association. Circ Arrhythm Electrophysiol 2022; 15:e000084.</a></li><li><a class="nounderline abstract_t">Valente AM, Cook S, Festa P, et al. Multimodality imaging guidelines for patients with repaired tetralogy of fallot: a report from the AmericanSsociety of Echocardiography: developed in collaboration with the Society for Cardiovascular Magnetic Resonance and the Society for Pediatric Radiology. J Am Soc Echocardiogr 2014; 27:111.</a></li><li><a class="nounderline abstract_t">Lindberg HL, Saatvedt K, Seem E, et al. Single-center 50 years' experience with surgical management of tetralogy of Fallot. Eur J Cardiothorac Surg 2011; 40:538.</a></li><li><a class="nounderline abstract_t">Bakhtiary F, Dähnert I, Leontyev S, et al. Outcome and incidence of re-intervention after surgical repair of tetralogy of fallot. J Card Surg 2013; 28:59.</a></li><li><a class="nounderline abstract_t">Park CS, Lee JR, Lim HG, et al. The long-term result of total repair for tetralogy of Fallot. Eur J Cardiothorac Surg 2010; 38:311.</a></li><li><a class="nounderline abstract_t">Hickey EJ, Veldtman G, Bradley TJ, et al. Functional health status in adult survivors of operative repair of tetralogy of fallot. Am J Cardiol 2012; 109:873.</a></li><li><a class="nounderline abstract_t">Frigiola A, Hughes M, Turner M, et al. Physiological and phenotypic characteristics of late survivors of tetralogy of fallot repair who are free from pulmonary valve replacement. Circulation 2013; 128:1861.</a></li><li><a class="nounderline abstract_t">Geva T, Sandweiss BM, Gauvreau K, et al. Factors associated with impaired clinical status in long-term survivors of tetralogy of Fallot repair evaluated by magnetic resonance imaging. J Am Coll Cardiol 2004; 43:1068.</a></li><li><a class="nounderline abstract_t">Davlouros PA, Kilner PJ, Hornung TS, et al. Right ventricular function in adults with repaired tetralogy of Fallot assessed with cardiovascular magnetic resonance imaging: detrimental role of right ventricular outflow aneurysms or akinesia and adverse right-to-left ventricular interaction. J Am Coll Cardiol 2002; 40:2044.</a></li><li><a class="nounderline abstract_t">Mueller AS, McDonald DM, Singh HS, Ginns JN. Heart failure in adult congenital heart disease: tetralogy of Fallot. Heart Fail Rev 2020; 25:583.</a></li><li><a class="nounderline abstract_t">Broberg CS, Aboulhosn J, Mongeon FP, et al. Prevalence of left ventricular systolic dysfunction in adults with repaired tetralogy of fallot. Am J Cardiol 2011; 107:1215.</a></li><li><a class="nounderline abstract_t">Roche SL, Grosse-Wortmann L, Friedberg MK, et al. Exercise echocardiography demonstrates biventricular systolic dysfunction and reveals decreased left ventricular contractile reserve in children after tetralogy of Fallot repair. J Am Soc Echocardiogr 2015; 28:294.</a></li><li><a class="nounderline abstract_t">Hennein HA, Mosca RS, Urcelay G, et al. Intermediate results after complete repair of tetralogy of Fallot in neonates. J Thorac Cardiovasc Surg 1995; 109:332.</a></li><li><a class="nounderline abstract_t">Dohlen G, Chaturvedi RR, Benson LN, et al. Stenting of the right ventricular outflow tract in the symptomatic infant with tetralogy of Fallot. Heart 2009; 95:142.</a></li><li><a class="nounderline abstract_t">Niwa K, Siu SC, Webb GD, Gatzoulis MA. Progressive aortic root dilatation in adults late after repair of tetralogy of Fallot. Circulation 2002; 106:1374.</a></li><li><a class="nounderline abstract_t">Nagy CD, Alejo DE, Corretti MC, et al. Tetralogy of Fallot and aortic root dilation: a long-term outlook. Pediatr Cardiol 2013; 34:809.</a></li><li><a class="nounderline abstract_t">Mongeon FP, Gurvitz MZ, Broberg CS, et al. Aortic root dilatation in adults with surgically repaired tetralogy of fallot: a multicenter cross-sectional study. Circulation 2013; 127:172.</a></li><li><a class="nounderline abstract_t">Havers-Borgersen E, Butt JH, Smerup M, et al. Incidence of Infective Endocarditis Among Patients With Tetralogy of Fallot. J Am Heart Assoc 2021; 10:e022445.</a></li><li><a class="nounderline abstract_t">Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 2000; 356:975.</a></li><li><a class="nounderline abstract_t">Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institutional study. Circulation 2010; 122:868.</a></li><li><a class="nounderline abstract_t">Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005; 26:2325.</a></li><li><a class="nounderline abstract_t">Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol 1997; 30:1368.</a></li><li><a class="nounderline abstract_t">Brouwer C, Kapel GFL, Jongbloed MRM, et al. Noninvasive Identification of Ventricular Tachycardia-Related Anatomical Isthmuses in Repaired Tetralogy of Fallot: What Is the Role of the 12-Lead Ventricular Tachycardia Electrocardiogram. JACC Clin Electrophysiol 2018; 4:1308.</a></li><li><a class="nounderline abstract_t">Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. Circulation 2007; 116:2241.</a></li><li><a class="nounderline abstract_t">Sabate Rotes A, Connolly HM, Warnes CA, et al. Ventricular arrhythmia risk stratification in patients with tetralogy of Fallot at the time of pulmonary valve replacement. Circ Arrhythm Electrophysiol 2015; 8:110.</a></li><li><a class="nounderline abstract_t">Bessière F, Gardey K, Bouzeman A, et al. Impact of Pulmonary Valve Replacement on Ventricular Arrhythmias in Patients With Tetralogy of Fallot and Implantable Cardioverter-Defibrillator. JACC Clin Electrophysiol 2021; 7:1285.</a></li><li><a class="nounderline abstract_t">Nollert G, Fischlein T, Bouterwek S, et al. Long-term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair. J Am Coll Cardiol 1997; 30:1374.</a></li><li><a class="nounderline abstract_t">Garson A Jr, McNamara DG. Sudden death in a pediatric cardiology population, 1958 to 1983: relation to prior arrhythmias. J Am Coll Cardiol 1985; 5:134B.</a></li><li><a class="nounderline abstract_t">Diller GP, Kempny A, Alonso-Gonzalez R, et al. Survival Prospects and Circumstances of Death in Contemporary Adult Congenital Heart Disease Patients Under Follow-Up at a Large Tertiary Centre. Circulation 2015; 132:2118.</a></li><li><a class="nounderline abstract_t">Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol 1998; 32:245.</a></li><li><a class="nounderline abstract_t">Cullen S, Celermajer DS, Franklin RC, et al. Prognostic significance of ventricular arrhythmia after repair of tetralogy of Fallot: a 12-year prospective study. J Am Coll Cardiol 1994; 23:1151.</a></li><li><a class="nounderline abstract_t">Maskatia SA, Spinner JA, Morris SA, et al. Effect of branch pulmonary artery stenosis on right ventricular volume overload in patients with tetralogy of fallot after initial surgical repair. Am J Cardiol 2013; 111:1355.</a></li><li><a class="nounderline abstract_t">Steeds RP, Oakley D. Predicting late sudden death from ventricular arrhythmia in adults following surgical repair of tetralogy of Fallot. QJM 2004; 97:7.</a></li><li><a class="nounderline abstract_t">Valente AM, Gauvreau K, Assenza GE, et al. Contemporary predictors of death and sustained ventricular tachycardia in patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort. Heart 2014; 100:247.</a></li><li><a class="nounderline abstract_t">Possner M, Tseng SY, Alahdab F, et al. Risk Factors for Mortality and Ventricular Tachycardia in Patients With Repaired Tetralogy of Fallot: A Systematic Review and Meta-analysis. Can J Cardiol 2020; 36:1815.</a></li><li><a class="nounderline abstract_t">Atallah J, Gonzalez Corcia MC, Walsh EP, Participating Members of the Pediatric and Congenital Electrophysiology Society. Ventricular Arrhythmia and Life-Threatening Events in Patients With Repaired Tetralogy of Fallot. Am J Cardiol 2020; 132:126.</a></li><li><a class="nounderline abstract_t">Buechel ER, Dave HH, Kellenberger CJ, et al. Remodelling of the right ventricle after early pulmonary valve replacement in children with repaired tetralogy of Fallot: assessment by cardiovascular magnetic resonance. Eur Heart J 2005; 26:2721.</a></li><li><a class="nounderline abstract_t">Discigil B, Dearani JA, Puga FJ, et al. Late pulmonary valve replacement after repair of tetralogy of Fallot. J Thorac Cardiovasc Surg 2001; 121:344.</a></li><li><a class="nounderline abstract_t">van Straten A, Vliegen HW, Lamb HJ, et al. Time course of diastolic and systolic function improvement after pulmonary valve replacement in adult patients with tetralogy of Fallot. J Am Coll Cardiol 2005; 46:1559.</a></li><li><a class="nounderline abstract_t">Adamson L, Vohra HA, Haw MP. Does pulmonary valve replacement post repair of tetralogy of Fallot improve right ventricular function? Interact Cardiovasc Thorac Surg 2009; 9:520.</a></li><li><a class="nounderline abstract_t">Ferraz Cavalcanti PE, Sá MP, Santos CA, et al. Pulmonary valve replacement after operative repair of tetralogy of Fallot: meta-analysis and meta-regression of 3,118 patients from 48 studies. J Am Coll Cardiol 2013; 62:2227.</a></li><li><a class="nounderline abstract_t">Bokma JP, Geva T, Sleeper LA, et al. Improved Outcomes After Pulmonary Valve Replacement in Repaired Tetralogy of Fallot. J Am Coll Cardiol 2023; 81:2075.</a></li><li><a class="nounderline abstract_t">Marelli A, Beauchesne L, Colman J, et al. Canadian Cardiovascular Society 2022 Guidelines for Cardiovascular Interventions in Adults With Congenital Heart Disease. Can J Cardiol 2022; 38:862.</a></li><li><a class="nounderline abstract_t">Waldmann V, Bessière F, Gardey K, et al. Systematic Electrophysiological Study Prior to Pulmonary Valve Replacement in Tetralogy of Fallot: A Prospective Multicenter Study. Circ Arrhythm Electrophysiol 2023; 16:e011745.</a></li><li><a class="nounderline abstract_t">Egbe AC, Miranda WR, Said SM, et al. Risk stratification and clinical outcomes after surgical pulmonary valve replacement. Am Heart J 2018; 206:105.</a></li><li><a class="nounderline abstract_t">Therrien J, Provost Y, Merchant N, et al. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol 2005; 95:779.</a></li><li><a class="nounderline abstract_t">Oosterhof T, van Straten A, Vliegen HW, et al. Preoperative thresholds for pulmonary valve replacement in patients with corrected tetralogy of Fallot using cardiovascular magnetic resonance. Circulation 2007; 116:545.</a></li><li><a class="nounderline abstract_t">Lee C, Kim YM, Lee CH, et al. Outcomes of pulmonary valve replacement in 170 patients with chronic pulmonary regurgitation after relief of right ventricular outflow tract obstruction: implications for optimal timing of pulmonary valve replacement. J Am Coll Cardiol 2012; 60:1005.</a></li><li><a class="nounderline abstract_t">Van den Eynde J, Sá MPBO, Vervoort D, et al. Pulmonary Valve Replacement in Tetralogy of Fallot: An Updated Meta-Analysis. Ann Thorac Surg 2022; 113:1036.</a></li><li><a class="nounderline abstract_t">Therrien J, Siu SC, McLaughlin PR, et al. Pulmonary valve replacement in adults late after repair of tetralogy of fallot: are we operating too late? J Am Coll Cardiol 2000; 36:1670.</a></li><li><a class="nounderline abstract_t">Eyskens B, Reybrouck T, Bogaert J, et al. Homograft insertion for pulmonary regurgitation after repair of tetralogy of fallot improves cardiorespiratory exercise performance. Am J Cardiol 2000; 85:221.</a></li><li><a class="nounderline abstract_t">Lurz P, Coats L, Khambadkone S, et al. Percutaneous pulmonary valve implantation: impact of evolving technology and learning curve on clinical outcome. Circulation 2008; 117:1964.</a></li><li><a class="nounderline abstract_t">Zahn EM, Hellenbrand WE, Lock JE, McElhinney DB. Implantation of the melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early results from the u.s. Clinical trial. J Am Coll Cardiol 2009; 54:1722.</a></li><li><a class="nounderline abstract_t">Khambadkone S, Coats L, Taylor A, et al. Percutaneous pulmonary valve implantation in humans: results in 59 consecutive patients. Circulation 2005; 112:1189.</a></li><li><a class="nounderline abstract_t">Cheatham JP, Hellenbrand WE, Zahn EM, et al. Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial. Circulation 2015; 131:1960.</a></li><li><a class="nounderline abstract_t">Wilson WM, Benson LN, Osten MD, et al. Transcatheter Pulmonary Valve Replacement With the Edwards Sapien System: The Toronto Experience. JACC Cardiovasc Interv 2015; 8:1819.</a></li><li><a class="nounderline abstract_t">Daily JA, Tang X, Angtuaco M, et al. Transcatheter Versus Surgical Pulmonary Valve Replacement in Repaired Tetralogy of Fallot. Am J Cardiol 2018; 122:498.</a></li><li><a class="nounderline abstract_t">O'Byrne ML, Glatz AC, Mercer-Rosa L, et al. Trends in pulmonary valve replacement in children and adults with tetralogy of fallot. Am J Cardiol 2015; 115:118.</a></li><li><a class="nounderline abstract_t">Zhou Y, Xiong T, Bai P, et al. Clinical outcomes of transcatheter versus surgical pulmonary valve replacement: a meta-analysis. J Thorac Dis 2019; 11:5343.</a></li><li><a class="nounderline abstract_t">McElhinney DB, Zhang Y, Levi DS, et al. Reintervention and Survival After Transcatheter Pulmonary Valve Replacement. J Am Coll Cardiol 2022; 79:18.</a></li><li><a class="nounderline abstract_t">Hallbergson A, Gauvreau K, Powell AJ, Geva T. Right ventricular remodeling after pulmonary valve replacement: early gains, late losses. Ann Thorac Surg 2015; 99:660.</a></li><li><a class="nounderline abstract_t">Tsang V, Tran PK. Invited commentary. Ann Thorac Surg 2015; 99:666.</a></li><li><a class="nounderline abstract_t">Stulak JM, Dearani JA, Burkhart HM, et al. The increasing use of mechanical pulmonary valve replacement over a 40-year period. Ann Thorac Surg 2010; 90:2009.</a></li><li><a class="nounderline abstract_t">Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Heart Rhythm 2014; 11:e102.</a></li><li><a class="nounderline abstract_t">Bokma JP, Winter MM, Vehmeijer JT, et al. QRS fragmentation is superior to QRS duration in predicting mortality in adults with tetralogy of Fallot. Heart 2017; 103:666.</a></li><li><a class="nounderline abstract_t">Khairy P. Programmed ventricular stimulation for risk stratification in patients with tetralogy of Fallot: a Bayesian perspective. Nat Clin Pract Cardiovasc Med 2007; 4:292.</a></li><li><a class="nounderline abstract_t">Rivas-Gándara N, Dos-Subirá L, Francisco-Pascual J, et al. Substrate characterization of the right ventricle in repaired tetralogy of Fallot using late enhancement cardiac magnetic resonance. Heart Rhythm 2021; 18:1868.</a></li><li><a class="nounderline abstract_t">Saglietto A, Falasconi G, Penela D, et al. Cardiac magnetic resonance-aided ventricular tachycardia substrate ablation in corrected tetralogy of Fallot. J Interv Card Electrophysiol 2023; 66:1317.</a></li><li><a class="nounderline abstract_t">Bouyer B, Jalal Z, Daniel Ramirez F, et al. Electrophysiological study prior to planned pulmonary valve replacement in patients with repaired tetralogy of Fallot. J Cardiovasc Electrophysiol 2023; 34:1395.</a></li><li><a class="nounderline abstract_t">Vehmeijer JT, Koyak Z, Leerink JM, et al. Identification of patients at risk of sudden cardiac death in congenital heart disease: The PRospEctiVE study on implaNTable cardIOverter defibrillator therapy and suddeN cardiac death in Adults with Congenital Heart Disease (PREVENTION-ACHD). Heart Rhythm 2021; 18:785.</a></li><li><a class="nounderline abstract_t">Vehmeijer JT, Koyak Z, Zwinderman AH, et al. PREVENTION-ACHD: PRospEctiVE study on implaNTable cardioverter-defibrillator therapy and suddeN cardiac death in Adults with Congenital Heart Disease; Rationale and Design. Neth Heart J 2019; 27:474.</a></li><li><a class="nounderline abstract_t">Moore JP, Aboulhosn JA, Zeppenfeld K, et al. Rationale and Design of the Multicenter Catheter Ablation of Ventricular Tachycardia Before Transcatheter Pulmonary Valve Replacement in Repaired Tetralogy of Fallot Study. Am J Cardiol 2023; 204:14.</a></li><li><a class="nounderline abstract_t">Moore JP, Aboulhosn JA, Khairy P. Electrophysiology testing before transcatheter pulmonary valve replacement in patients with repaired tetralogy of Fallot. Eur Heart J 2023; 44:3228.</a></li><li><a class="nounderline abstract_t">Gengsakul A, Harris L, Bradley TJ, et al. The impact of pulmonary valve replacement after tetralogy of Fallot repair: a matched comparison. Eur J Cardiothorac Surg 2007; 32:462.</a></li><li><a class="nounderline abstract_t">Van Hare GF, Ackerman MJ, Evangelista JA, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 4: Congenital Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation 2015; 132:e281.</a></li><li><a class="nounderline abstract_t">Kapel GFL, Brouwer C, Jalal Z, et al. Slow Conducting Electroanatomic Isthmuses: An Important Link Between QRS Duration and Ventricular Tachycardia in Tetralogy of Fallot. JACC Clin Electrophysiol 2018; 4:781.</a></li><li><a class="nounderline abstract_t">Burton ME, Leon AR. Radiofrequency catheter ablation of right ventricular outflow tract tachycardia late after complete repair of tetralogy of Fallot using the pace mapping technique. Pacing Clin Electrophysiol 1993; 16:2319.</a></li><li><a class="nounderline abstract_t">Goldner BG, Cooper R, Blau W, Cohen TJ. Radiofrequency catheter ablation as a primary therapy for treatment of ventricular tachycardia in a patient after repair of tetralogy of Fallot. Pacing Clin Electrophysiol 1994; 17:1441.</a></li><li><a class="nounderline abstract_t">Biblo LA, Carlson MD. Transcatheter radiofrequency ablation of ventricular tachycardia following surgical correction of tetralogy of Fallot. Pacing Clin Electrophysiol 1994; 17:1556.</a></li><li><a class="nounderline abstract_t">Cohen MI, Khairy P, Zeppenfeld K, et al. Preventing Arrhythmic Death in Patients With Tetralogy of Fallot: JACC Review Topic of the Week. J Am Coll Cardiol 2021; 77:761.</a></li><li><a class="nounderline abstract_t">Kawada S, Chakraborty P, Downar E, et al. The Role of Ablation in Prevention of Recurrent Implantable Cardioverter Defibrillator Shocks in Patients With Tetralogy of Fallot. CJC Open 2021; 3:619.</a></li><li><a class="nounderline abstract_t">Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation 2008; 117:363.</a></li><li><a class="nounderline abstract_t">Yap SC, Roos-Hesselink JW, Hoendermis ES, et al. Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study. Eur Heart J 2007; 28:1854.</a></li><li><a class="nounderline abstract_t">Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation 2004; 109:1994.</a></li><li><a class="nounderline abstract_t">Waldmann V, Bouzeman A, Duthoit G, et al. Long-Term Follow-Up of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator: The DAI-T4F Nationwide Registry. Circulation 2020; 142:1612.</a></li><li><a class="nounderline abstract_t">Veldtman GR, Connolly HM, Grogan M, et al. Outcomes of pregnancy in women with tetralogy of Fallot. J Am Coll Cardiol 2004; 44:174.</a></li><li><a class="nounderline abstract_t">Singh H, Bolton PJ, Oakley CM. Pregnancy after surgical correction of tetralogy of Fallot. Br Med J (Clin Res Ed) 1982; 285:168.</a></li><li><a class="nounderline abstract_t">Nissenkorn A, Friedman S, Schonfeld A, Ovadia J. Fetomaternal outcome in pregnancies after total correction of the tetralogy of Fallot. Int Surg 1984; 69:125.</a></li><li><a class="nounderline abstract_t">Meijer JM, Pieper PG, Drenthen W, et al. Pregnancy, fertility, and recurrence risk in corrected tetralogy of Fallot. Heart 2005; 91:801.</a></li><li><a class="nounderline abstract_t">Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.</a></li><li><a class="nounderline abstract_t">Beauchesne LM, Warnes CA, Connolly HM, et al. Prevalence and clinical manifestations of 22q11.2 microdeletion in adults with selected conotruncal anomalies. J Am Coll Cardiol 2005; 45:595.</a></li></ol></div><div id="topicVersionRevision">Topic 141526 Version 2.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21123635" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tetralogy of fallot repair in patients 40 years or older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2458076" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Results of total correction of tetralogy of Fallot performed in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10410289" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Surgical repair of tetralogy of Fallot in adults today.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586767" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860028" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2020 ESC Guidelines for the management of adult congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36263773" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Arrhythmias in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24468055" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Multimodality imaging guidelines for patients with repaired tetralogy of fallot: a report from the AmericanSsociety of Echocardiography: developed in collaboration with the Society for Cardiovascular Magnetic Resonance and the Society for Pediatric Radiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21354809" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Single-center 50 years' experience with surgical management of tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23189926" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Outcome and incidence of re-intervention after surgical repair of tetralogy of fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20346688" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The long-term result of total repair for tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22244382" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Functional health status in adult survivors of operative repair of tetralogy of fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24065608" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Physiological and phenotypic characteristics of late survivors of tetralogy of fallot repair who are free from pulmonary valve replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028368" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Factors associated with impaired clinical status in long-term survivors of tetralogy of Fallot repair evaluated by magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12475468" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Right ventricular function in adults with repaired tetralogy of Fallot assessed with cardiovascular magnetic resonance imaging: detrimental role of right ventricular outflow aneurysms or akinesia and adverse right-to-left ventricular interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31925611" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Heart failure in adult congenital heart disease: tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349477" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence of left ventricular systolic dysfunction in adults with repaired tetralogy of fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25459500" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Exercise echocardiography demonstrates biventricular systolic dysfunction and reveals decreased left ventricular contractile reserve in children after tetralogy of Fallot repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7531798" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intermediate results after complete repair of tetralogy of Fallot in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18332061" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Stenting of the right ventricular outflow tract in the symptomatic infant with tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12221055" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Progressive aortic root dilatation in adults late after repair of tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23080541" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tetralogy of Fallot and aortic root dilation: a long-term outlook.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23224208" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Aortic root dilatation in adults with surgically repaired tetralogy of fallot: a multicenter cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34730003" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence of Infective Endocarditis Among Patients With Tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11041398" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20713900" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institutional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996978" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9350941" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30336877" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Noninvasive Identification of Ventricular Tachycardia-Related Anatomical Isthmuses in Repaired Tetralogy of Fallot: What Is the Role of the 12-Lead Ventricular Tachycardia Electrocardiogram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17967973" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25416756" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ventricular arrhythmia risk stratification in patients with tetralogy of Fallot at the time of pulmonary valve replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33933408" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Impact of Pulmonary Valve Replacement on Ventricular Arrhythmias in Patients With Tetralogy of Fallot and Implantable Cardioverter-Defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9350942" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Long-term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3998330" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Sudden death in a pediatric cardiology population, 1958 to 1983: relation to prior arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26369353" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Survival Prospects and Circumstances of Death in Contemporary Adult Congenital Heart Disease Patients Under Follow-Up at a Large Tertiary Centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669277" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8144782" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prognostic significance of ventricular arrhythmia after repair of tetralogy of Fallot: a 12-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23411101" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of branch pulmonary artery stenosis on right ventricular volume overload in patients with tetralogy of fallot after initial surgical repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14702506" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Predicting late sudden death from ventricular arrhythmia in adults following surgical repair of tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24179163" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Contemporary predictors of death and sustained ventricular tachycardia in patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32416063" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk Factors for Mortality and Ventricular Tachycardia in Patients With Repaired Tetralogy of Fallot: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32778337" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ventricular Arrhythmia and Life-Threatening Events in Patients With Repaired Tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214832" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Remodelling of the right ventricle after early pulmonary valve replacement in children with repaired tetralogy of Fallot: assessment by cardiovascular magnetic resonance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174741" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Late pulmonary valve replacement after repair of tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16226185" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Time course of diastolic and systolic function improvement after pulmonary valve replacement in adult patients with tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19567499" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Does pulmonary valve replacement post repair of tetralogy of Fallot improve right ventricular function?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24080109" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pulmonary valve replacement after operative repair of tetralogy of Fallot: meta-analysis and meta-regression of 3,118 patients from 48 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37225360" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Improved Outcomes After Pulmonary Valve Replacement in Repaired Tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35460862" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Canadian Cardiovascular Society 2022 Guidelines for Cardiovascular Interventions in Adults With Congenital Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37170812" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Systematic Electrophysiological Study Prior to Pulmonary Valve Replacement in Tetralogy of Fallot: A Prospective Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30343246" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Risk stratification and clinical outcomes after surgical pulmonary valve replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15757612" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620511" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Preoperative thresholds for pulmonary valve replacement in patients with corrected tetralogy of Fallot using cardiovascular magnetic resonance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22921969" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Outcomes of pulmonary valve replacement in 170 patients with chronic pulmonary regurgitation after relief of right ventricular outflow tract obstruction: implications for optimal timing of pulmonary valve replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33378694" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pulmonary Valve Replacement in Tetralogy of Fallot: An Updated Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11079675" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pulmonary valve replacement in adults late after repair of tetralogy of fallot: are we operating too late?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10955381" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Homograft insertion for pulmonary regurgitation after repair of tetralogy of fallot improves cardiorespiratory exercise performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391109" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Percutaneous pulmonary valve implantation: impact of evolving technology and learning curve on clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19850214" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Implantation of the melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early results from the u.s. Clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16103239" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Percutaneous pulmonary valve implantation in humans: results in 59 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25944758" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26718514" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Transcatheter Pulmonary Valve Replacement With the Edwards Sapien System: The Toronto Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30201112" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Transcatheter Versus Surgical Pulmonary Valve Replacement in Repaired Tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25456860" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Trends in pulmonary valve replacement in children and adults with tetralogy of fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32030252" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical outcomes of transcatheter versus surgical pulmonary valve replacement: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34991785" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Reintervention and Survival After Transcatheter Pulmonary Valve Replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25483002" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Right ventricular remodeling after pulmonary valve replacement: early gains, late losses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25639403" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Invited commentary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21095354" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The increasing use of mechanical pulmonary valve replacement over a 40-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24814377" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27803032" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : QRS fragmentation is superior to QRS duration in predicting mortality in adults with tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17522719" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Programmed ventricular stimulation for risk stratification in patients with tetralogy of Fallot: a Bayesian perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34098087" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Substrate characterization of the right ventricle in repaired tetralogy of Fallot using late enhancement cardiac magnetic resonance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36964886" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cardiac magnetic resonance-aided ventricular tachycardia substrate ablation in corrected tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37232426" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Electrophysiological study prior to planned pulmonary valve replacement in patients with repaired tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33465514" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Identification of patients at risk of sudden cardiac death in congenital heart disease: The PRospEctiVE study on implaNTable cardIOverter defibrillator therapy and suddeN cardiac death in Adults with Congenital Heart Disease (PREVENTION-ACHD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31270738" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : PREVENTION-ACHD: PRospEctiVE study on implaNTable cardioverter-defibrillator therapy and suddeN cardiac death in Adults with Congenital Heart Disease; Rationale and Design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37536198" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Rationale and Design of the Multicenter Catheter Ablation of Ventricular Tachycardia Before Transcatheter Pulmonary Valve Replacement in Repaired Tetralogy of Fallot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37551634" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Electrophysiology testing before transcatheter pulmonary valve replacement in patients with repaired tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17627832" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The impact of pulmonary valve replacement after tetralogy of Fallot repair: a matched comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26621645" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 4: Congenital Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29929672" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Slow Conducting Electroanatomic Isthmuses: An Important Link Between QRS Duration and Ventricular Tachycardia in Tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7508611" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Radiofrequency catheter ablation of right ventricular outflow tract tachycardia late after complete repair of tetralogy of Fallot using the pace mapping technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7971406" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Radiofrequency catheter ablation as a primary therapy for treatment of ventricular tachycardia in a patient after repair of tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7991428" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Transcatheter radiofrequency ablation of ventricular tachycardia following surgical correction of tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33573746" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Preventing Arrhythmic Death in Patients With Tetralogy of Fallot: JACC Review Topic of the Week.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34027366" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The Role of Ablation in Prevention of Recurrent Implantable Cardioverter Defibrillator Shocks in Patients With Tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172030" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Implantable cardioverter-defibrillators in tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030523" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051640" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32998542" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Long-Term Follow-Up of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator: The DAI-T4F Nationwide Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15234429" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Outcomes of pregnancy in women with tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6807393" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Pregnancy after surgical correction of tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6500876" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Fetomaternal outcome in pregnancies after total correction of the tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894783" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pregnancy, fertility, and recurrence risk in corrected tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17572244" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Outcome of pregnancy in women with congenital heart disease: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708709" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Prevalence and clinical manifestations of 22q11.2 microdeletion in adults with selected conotruncal anomalies.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
